Fig. 1 · Structure

Documents & Downloads

Procaterol HCl

Cat. No. A11905 CAS 62929-91-3
Procaterol is a short-acting β2-adrenergic receptor agonist with Kp of 8 nM, used for the treatment of asthma

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Procaterol HCl Research Summary

This section summarizes 3 in vitro studies of Procaterol HCl from 3 published references. In vitro models include gastric cancer cells.

Procaterol HCl In Vitro Studies

Procaterol inhibited colony formation in gastric cancer cells compared with vehicle control. In tracheal rings from male Hartley guinea pigs, Procaterol inhibited MCh-induced contraction compared with the control response to MCh in a design including indomethacin. In tracheal smooth muscle strips from male Hartley guinea pigs, Procaterol reduced MCh-induced tension compared with the control response to MCh in a design including indomethacin. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibiting Colony Formation of Gastric Cancer Cell Lines

Cell-based study · gastric cancer cells [1]

Procaterol has a dramatic effect on inhibiting colony formation of gastric cancer cell lines. Colony formation of gastric cancer cells with vehicle control and procaterol (0.5 μM) treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Colony formationReported result procaterol (0.5 μM): a dramatic effect on inhibiting colony formation of gastric cancer cell lines[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μM
Exposure duration
1 to 2 weeks
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Procaterol

The paper names Procaterol without stating the salt or form; not verified as the hydrochloride form supplied as A11905. No dose conversion or lot validation.

Results > Procaterol is a CDK12 inhibitor (S65); Materials and methods > Cell assays: cell viability assay, colony formation assay, foci assay, cell cycle and apoptosis analysis (S85); Figure 7 legend (S243)

Colony formation: Colony formation; comparator: vehicle control — Results > Procaterol is a CDK12 inhibitor (S65); Figure 7 legend (S243)

Inhibition of Induced Contraction in Guinea Pig Tracheal Rings

Cell-based study · Male Hartley guinea pigs; tracheal ring with three segments of cartilage; n = 8 [2]

In tracheal rings from male Hartley guinea pigs, Procaterol at 10 nM produced 52.2 ± 6.9 percent inhibition of MCh-induced contraction compared with the control response to MCh.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MCh (10 μM)-induced contractioncontraction 52.2 ± 6.9 percent inhibition[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM
Method
2-mL organ bath
Vehicle
normal bathing solution
Co-treatment
Other interventions in this design: MCh 10 μM; indomethacin 1 μM. Compound effect isolated by the comparison: control response to MCh (1 or 10 μM).
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Procaterol

The paper names Procaterol without stating the salt or form; not verified as the hydrochloride form supplied as A11905. No dose conversion or lot validation.

2. Results > 2.1. Synergism in the Combination of β2-Adrenergic Receptors with Muscarinic Receptor Antagonists (S2); 4. Materials and Methods > 4.1. Tissue Preparation and Tension Records (S59, S60, S65, S68); 4. Materials and Methods > 4.5. Statistical Analysis (S90); Figure 2 legend (S99)

MCh (10 μM)-induced contraction: MCh (10 μM)-induced contraction; comparator: control response to MCh (1 or 10 μM) — 2. Results > 2.1. Synergism in the Combination of β2-Adrenergic Receptors with Muscarinic Receptor Antagonists (S2)

Reduction of Induced Tension in Guinea Pig Tracheal Muscle

Cell-based study · strips of tracheal smooth muscle; male Hartley guinea pigs; n = 5 [3]

In tracheal smooth muscle strips from male Hartley guinea pigs, Procaterol at 1 nM was administered cumulatively to tissue precontracted with MCh. It reduced MCh-induced tension by 37.0% ± 9.1% compared with the control response to MCh.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MCh-induced tensionMCh-induced tension 37.0% ± 9.1%[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 nM
Exposure duration
Each reagent at each concentration was administered for 15 min (except MCh).
Method
administered cumulatively to tissue precontracted with MCh
Vehicle
Normal bathing solution
Co-treatment
Other interventions in this design: MCh 1 μM; Indomethacin 2 µM. Compound effect isolated by the comparison: control response to MCh (1 µM).
Methods and source locations

Compound reported in the paper: Procaterol

The paper names Procaterol without stating the salt or form; not verified as the hydrochloride form supplied as A11905. No dose conversion or lot validation.

2. Results > 2.1. Inhibitory Effects of Procaterol, Salbutamol, and Glycopyrronium on Tension and Intracellular Ca2+ Concentration in Contracted Muscle (S1); 2. Results > 2.2. Effects of Procaterol and Salbutamol Combined with Glycopyrronium on Tension and Intracellular Ca2+ Concentration in Contracted Muscle (S6); 4. Experimental Section > 4.1. Tissue Preparation and Bathing Solution (S58, S60); 4. Experimental Section > 4.2. Isometric Tension Recording and Measurement of Fura-2 Fluorescence...

MCh-induced tension: MCh-induced tension; comparator: control response to MCh (1 µM) — 2. Results > 2.2. Effects of Procaterol and Salbutamol Combined with Glycopyrronium on Tension and Intracellular Ca2+ Concentration in Contracted Muscle (S6)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 62929-91-3
Formula C16H22N2O3.HCl
Molecular Weight 326.82
SMILES
CC[C@@H]([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 59 mg/mL (180.52 mM)
Water 59 mg/mL (180.52 mM)
Ethanol 3 mg/mL (9.17 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Procaterol HCl Research References

  1. [1] Liu H, Shin SH, Chen H, et al. CDK12 and PAK2 as novel therapeutic targets for human gastric cancer. Theranostics (2020). PMID: 32483448 DOI: 10.7150/thno.46137 Source material
  2. [2] Kume H, Nishiyama O, Isoya T, et al. Involvement of Allosteric Effect and KCa Channels in Crosstalk between β₂-Adrenergic and Muscarinic M₂ Receptors in Airway Smooth Muscle. Int J Mol Sci (2018). PMID: 29987243 DOI: 10.3390/ijms19071999 Source material
  3. [3] Fukunaga K, Kume H, Oguma T, et al. Involvement of Ca2+ Signaling in the Synergistic Effects between Muscarinic Receptor Antagonists and β₂-Adrenoceptor Agonists in Airway Smooth Muscle. Int J Mol Sci (2016). PMID: 27657061 DOI: 10.3390/ijms17091590 Source material

Added to your cart

View Cart Checkout
Loading...